![]() |
|
|
Vol. 59, Issue 2, 349-357, February 2001
Institute of Pharmacology, University of Heidelberg, Heidelberg,
Germany (A.L., C.S., H.L., U.S.); and Department of Medicinal
Chemistry, Latvian Institute of Organic Synthesis, Riga, Latvia (V.A.,
I.K.)
Nicotinic acid is a lipid-lowering agent widely used to treat
hypertriglyceridemia and to elevate low high density lipoprotein levels. However, the underlying mechanisms are poorly understood. In
this study, G protein activation by nicotinic acid and derivatives was
assessed as stimulation of guanosine
5'-(
-[35S]-thio)triphosphate
([35S]GTP
S) binding, and [3H]nicotinic
acid was used for specific labeling of binding sites. Nicotinic acid
(EC50 ~1 µM) stimulated [35S]GTP
S
binding in membranes from rat adipocytes and spleen, but not from other
tissues. G protein activation in adipocyte membranes in the presence of
maximally activating concentrations of the selective A1
adenosine receptor agonist
2-chloro-N6-cyclopentyladenosine and
nicotinic acid was almost additive, indicating that G proteins of
mostly distinct pools were activated by these agonists. G protein
activation by nicotinic acid and related substances in spleen and
adipocytes revealed identical pharmacological profiles.
[3H]Nicotinic acid specifically detected guanine
nucleotide-sensitive binding sites of identical pharmacology in
adipocyte and spleen membranes. The site of action of nicotinic acid is
distinct from other G protein-coupled receptors. These data indicate
that nicotinic acid most probably acts on a specific G protein-coupled receptor.
This article has been cited by other articles:
![]() |
S. C. Cheng, D. O. Young, Y. Huang, J. A. Delmez, and D. W. Coyne A Randomized, Double-Blind, Placebo-Controlled Trial of Niacinamide for Reduction of Phosphorus in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1131 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Richman, M. Kanemitsu-Parks, I. Gaidarov, J. S. Cameron, P. Griffin, H. Zheng, N. C. Guerra, L. Cham, D. Maciejewski-Lenoir, D. P. Behan, et al. Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors J. Biol. Chem., June 22, 2007; 282(25): 18028 - 18036. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Cusi, S. Kashyap, A. Gastaldelli, M. Bajaj, and E. Cersosimo Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1775 - E1781. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.F. Oliver Sudden cardiac death: the lost fatty acid hypothesis QJM, October 1, 2006; 99(10): 701 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wise, S. M. Foord, N. J. Fraser, A. A. Barnes, N. Elshourbagy, M. Eilert, D. M. Ignar, P. R. Murdock, K. Steplewski, A. Green, et al. Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid J. Biol. Chem., March 7, 2003; 278(11): 9869 - 9874. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Liu and J. S. Dillon Dehydroepiandrosterone Activates Endothelial Cell Nitric-oxide Synthase by a Specific Plasma Membrane Receptor Coupled to Galpha i2,3 J. Biol. Chem., June 7, 2002; 277(24): 21379 - 21388. [Abstract] [Full Text] [PDF] |
||||